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The balance between protective immunity and immunopathology often determines the
fate of the virus-infected host. How rapidly virus is cleared is a function of initial viral
load, viral replication rate, and efficiency of the immune response. Here, we demonstrate,
with three different inocula of lymphocytic choriomeningitis virus (LCMV), how the race
between virus replication and T cell responses can result in different disease outcomes. A
low dose of LCMV generated efficient CD8 T effector cells, which cleared the virus with
minimal lung and liver pathology. A high dose of LCMV resulted in clonal exhaustion of T
cell responses, viral persistence, and little immunopathology. An intermediate dose only
partially exhausted the T cell responses and resulted in significant mortality, and the sur-
viving mice developed viral persistence and massive immunopathology, including necrosis
of the lungs and liver. This suggests that for non-cytopathic viruses like LCMV, hepatitis C
virus, and hepatitis B virus, clonal exhaustion may be a protective mechanism preventing
severe immunopathology and death.
Keywords: clonal exhaustion, CD8,T cells, LCMV, immunopathology, lung, liver
INTRODUCTION
Because of the property of viruses to infect cells, peptide cleavage
products from many of their encoded proteins get incorporated
into nascent class I major histocompatibility complex (MHC)
molecules and get presented at the cell surface to CD8 T cells bear-
ing T cell receptors (TCR) specific for the peptide-MHC complex.
As a result, viral infections frequently stimulate very potent class
I-restricted CD8 T cell responses capable of perforin- or FasL-
dependent cytotoxicity, as well as IFNγ and TNFα production.
Indeed, CD8 T cells are essential regulators of viral infection, play-
ing important roles in the clearance of virus-infected cells and
sometimes causing damaging immunopathology (1). The rela-
tive balance between protective immunity and immunopathology
often determines the fate of the virus-infected host (2). A classic
example is that of lymphocytic choriomeningitis virus (LCMV),
where the same clone of T cells responsible for viral clearance
can mediate a severe leptomeningitis if the virus is replicating in
the brain (1, 3). The pathology that is induced by T cells dur-
ing an acute infection most likely results from the inflammatory
conditions brought about by the presence of high numbers of T
Abbreviations: ICS, intracellular cytokine staining; IFN, interferon; LCMV, lym-
phocytic choriomeningitis virus; TCR, T cell receptor; TNF, tumor necrosis
factor.
cells lysing infected tissues via perforin and FasL, producing pro-
inflammatory cytokines, including TNFα, and chemokines which
recruit even more cells. Important factors in how rapidly virus
is cleared include the initial viral load, rate of viral replication,
and the efficiency of the activated antigen-specific T cells. Here,
we demonstrate with three different inocula of LCMV clone 13
intravenously (i.v.) how the race between the virus and the T cell
response can result in completely different outcomes. Mice given
low doses of LCMV clone 13 developed a strong effector CD8 T cell
response, which cleared the virus. If the viral load becomes high
very rapidly it can result in clonal exhaustion of the T cell response
and viral persistence (4–7) associated with little immunopathol-
ogy, as was shown here in high dose LCMV clone13 infection.
Here, we also demonstrate that if the mice were given an inter-
mediate dose of LCMV clone 13, the immune response was able
to develop and exhausted more slowly, leaving time for massive
collateral damage and resulted in increased mortality with severe
lung and liver necrosis.
MATERIALS AND METHODS
MICE
C57BL/6 (B6, H-2b) and TCRβKO male mice were purchased
from The Jackson Laboratory (Bar Harbor, ME, USA) and Taconic
Farms (Germantown, NY, USA), respectively. Mice were used
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at 2–8 months of age. All mice were maintained under specific
pathogen-free conditions in the University of Massachusetts Med-
ical School, Department of Animal Medicine. All experiments were
done in compliance with institutional guidelines as approved by
the Institutional Animal Care and Use Committee at the University
of Massachusetts Medical School.
VIRUSES
Lymphocytic choriomeningitis virus (clone 13) is a RNA virus in
the Old World Arenavirus family, and was propagated in BHK21
baby hamster kidney cells (8).
INFECTION PROTOCOLS
Mice were inoculated i.v. with low dose, 2× 104 pfu; medium dose,
2× 105 pfu; and high dose, 2× 106 pfu of LCMV clone 13. Con-
trol naïve mice were either left uninoculated or were inoculated
with HBSS. The control mice were always age matched to the
experimental group and housed exactly the same in pathogen-free
conditions.
VIRUS TITRATION
Lymphocytic choriomeningitis virus titers in 10% tissue
homogenate from spleens and serum were determined by plaque
assays on ATCC vero cells, as described elsewhere (9).
PEPTIDES
Lymphocytic choriomeningitis virus epitopes NP396, Db
(FQPQNGQFI), GP33, Db (KAVYNFATC), NP205 epitope
(YTVKYPNL). Synthetic peptides were provided by Biosource
International (Camarillo, CA, USA) or 21st Century Biochemicals
(Marlboro, MA, USA) and used at a 90% level of purity.
CELL SURFACE AND TETRAMER STAINING BY FLOW CYTOMETRY
Single cell suspensions were prepared from splenocytes or periph-
eral blood. Erythrocytes were lysed with 0.84% NH4Cl solution.
FACS staining was done as previously described in 96-well plates
with fluorochrome-labeled mAbs, anti-CD8 (clone 53-6.7, BD
Pharmingen), anti-CD44 (clone IM7), and PD-1 (clone J43).
Tetramer staining was done as previously described using phy-
coerythrin (PE) and/or allophycocyanin (APC) labeled tetramers
(10). Samples were analyzed with a Becton Dickinson FACSCal-
ibur flow cytometer (San Jose, CA, USA) or a LSRII (San Jose,
CA, USA) and FlowJo software (Tree Star, Inc., Ashland, OR,
USA). All surface mAbs were purchased from BD Pharmingen, San
Diego, CA, USA or eBioscience, San Diego, CA, USA. MHC class I
peptide tetramers specific for LCMV-NP205/Kb, LCMV-NP396/Db,
and LCMV-GP33/Db were prepared as previously described (10).
INTRACELLULAR CYTOKINE STAINING
Cells (106) were stimulated either with medium, or 1–5µM syn-
thetic peptide as previously described (10). Intracellular cytokine-
producing cells were detected with anti-IFNγ (clone XMG1.2),
anti-TNFα (clone MP6-XT22), and anti-IL-2 (clone JES6-5H4)
mAbs. IgG-isotype mAbs were used in the same assay. The mAbs
were purchased from BD Pharmingen, San Diego, CA, USA or
eBioscience, San Diego, CA, USA. The samples were analyzed as
described above.
CD8 DEPLETION
Mice were injected i.p. on day-1 and -7 of LCMV clone 13 infection
with 100µg of CD8 (clone 2.43) antibody.
HISTOLOGY
At day 14 after LCMV challenge, lungs and livers from LCMV clone
13-infected mice were collected, fixed in 10% neutral buffered
formaldehyde and paraffin-embedded. Tissue sections (5µm)
were stained with hematoxylin and eosin and analyzed micro-
scopically by a pathologist. Scoring of lung pathology was graded
based on a scale outlined below and based on previously pub-
lished studies (11–13). Scoring of lung pathology was graded by
one pathologist, who was blinded in regards to treatments the mice
had received.
1. Mild interstitial mononuclear infiltrates, disorganized BALT,
perivascular edema.
2. Moderate interstitial mononuclear infiltrates, small amount of
organized BALT, pulmonary edema.
3. Moderate interstitial mononuclear infiltrates, pulmonary
edema, enhanced organized BALT, mild consolidation.
4. Severe interstitial mononuclear infiltrates, greatly enhanced
pulmonary edema, enhanced organized BALT, moderate con-
solidation and moderate necrotizing bronchiolitis.
5. Severe interstitial mononuclear infiltrates, greatly enhanced
pulmonary edema, enhanced organized BALT, severe consoli-
dation, severe necrotizing bronchiolitis and vasculitis involving
more than half of the lung.
The scoring on each individual mouse was done on four to five
different sections of the lung representing four to five different
lobes of the whole lung assessing both qualitative and quantita-
tive changes in histology. The histology photographs showing high
power views of a small portion of one lobe of the lung demon-
strate examples of the types of pathology observed in different
treatment groups, but evaluations of the whole lung were used for
scoring.
ALT ASSAY
Serum alanine aminotransferase (ALT) levels were determined
using an ALT UV-kinetic method reagent set (D-Tek, Bensalem,
PA, USA). Fifteen microliters of serum was mixed with 150µL of
substrate and absorbance at was read at 340 nm. ALT concentra-
tion was calculated as the average change in absorbance/min multi-
plied by 1768. ALT (IU/L) is equal to the change in absorbance/min
multiplied by total reaction volume (0.165 mL) *1000 to convert
IU/mL to IU/L. This is divided by the millimolar absorptivity of
NADH (6.22) multiplied by the sample volume (0.015 mL) mul-
tiplied by the light path (1.0 cm). This equation simplifies into the
change in absorbance/min multiplied by 1768.
STATISTICAL ANALYSES
The one-way ANOVA test with a Bonferroni post-test was used
when there were more than two groups. The Student’s t -test was
used as indicated in the figures when only comparing two groups.
The Mantel–Cox Mortality test was used for mortality studies.
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RESULTS
INCREASED IMMUNOPATHOLOGY AND MORTALITY DURING LCMV
MEDIUM DOSE INFECTION
We infected C57BL/6 mice intravenously with low dose
(2× 104 pfu), medium dose (2× 105 pfu), and high dose
(2× 106 pfu) LCMV clone 13 i.v. There was significantly higher
mortality in the medium dose group, with only 25% of mice sur-
viving at Day 13 (Figure 1A). Both the medium and high dose
groups experienced a rapid and significant >20% weight loss
beginning at day 6 after infection, with the high dose group start-
ing to recover after day 10 while the medium dose group did not
recover even by day 13 (Figures 1B,C). All of the mice that survived
the medium dose infection were persistently infected with LCMV,
similar to the high dose group. The dramatic immunopathology
was mediated by the T cell response, as demonstrated by the fact
that TCRβ KO mice infected with the medium dose did not have
any significant weight loss or death, in contrast to WT controls
(Figures 1A,C). The TCRβ KO mice had a slightly higher viral
load than the WT controls at day 13 post infection and yet did not
have pathology (log10 pfu/spleen: B6 5.7± 0.13 SEM; TCRβ KO
6.3± 0.13; n= 5/group; p< 0.02). The CD8 T cells were the major
T cell population involved in mediating this effect, as demon-
strated by depletion of CD8 T cells with mAb. B6 mice depleted of
CD8 T cells prior to infection with the medium dose of LCMV also
had significantly less weight loss and decreased mortality than the
WT controls (Figure 1C) without a significant difference in viral
load in the spleen at day 13 post infection (log10 pfu/spleen: B6
4.9± 0.5 SEM; anti-CD8 tx 5.3± 0.07 n= 5–9/group).
PARTIAL CLONAL EXHAUSTION IN THE MEDIUM DOSE-INFECTED MICE
Persistent infection leads to a disruption of the normal immun-
odominance hierarchy and function of CD8 T cell responses
during high dose LCMV clone 13 infection referred to as clonal
exhaustion (6, 14). Clonal exhaustion occurs by a stepwise loss of
function due to high antigen load and loss of CD4-help. Cells first
lose cytotoxic abilities, then IL-2 production followed by the ability
to produce TNFα and finally IFNγ. The final stage of exhaustion is
the deletion of antigen-specific cells by apoptosis making exhaus-
tion both a qualitative and quantitative. CD8 T cell functional
impairment occurs in a hierarchical fashion in chronically infected
mice. Production of IL-2 and the ability to lyse target cells in vitro
are the first functions compromised, followed by the ability to
make TNFα, while IFNγ production is most resistant to functional
exhaustion. Antigen appears to be the driving force for this loss of
function, since a strong correlation exists between the viral load
and the level of exhaustion (15). Epitopes presented at higher levels
in vivo result in physical deletion, such as NP396, while those pre-
sented at lower levels, such as GP33 and NP205, induce functional
exhaustion. These published data would suggest that antigen levels
drive the hierarchical loss of different CD8 T cell effector functions
during chronic infection, leading to distinct stages of functional
impairment and eventually to physical deletion of virus-specific T
cells. Thus, we determined the functionality of the epitope-specific
CD8 T cells in the three groups of mice by intracellular cytokine
staining (ICS) for the presence of IFNγ- and/or TNFα-producing
cells and calculating the ratio of IFNγ+TNFα+/IFNγ+ cells at
days 7 and 13 post infection. The high dose clone 13-infected mice
FIGURE 1 | Balance between viral load and CD8T cell response
determines disease outcome to LCMV clone 13 infection. (A) Increased
mortality in C57BL/6 mice infected with medium dose of LCMV clone 13
(2×105 pfu) i.v. as compared to low dose (2×104 pfu) or high dose
(2×106 pfu) depleted of CD8 T cells with anti-CD8 mAb or TCRβ KO mice
were protected from lethal effect of medium dose (#p=0.05; n=11–33
mice/group) (Mantel–Cox Mortality, #p<0.002). The symbols, which cannot
be discerned are all overlaid on the 100% line. (B) Increased weight loss in
both medium dose and high dose LCMV clone 13-infected mice, but high
dose began to regain weight at day 13 while medium dose do not (medium
vs. high, **p=0.008; medium vs. low, ***p=0.0002; n=11–12
mice/group). (C) Mice depleted of CD8 T cells with anti-CD8 mAb or TCRβ
KO mice were protected from weight loss during medium dose (medium
vs. TCRβ KO, ***p=0.0001; medium vs. CD8 depleted, ***p=0.0002;
TCRβ KO vs. CD8 depleted ***p=0.003, n=9–22 mice/group).
had significant exhaustion of NP396-, GP33-, and NP205-specific
responses, as defined by loss of the double positive IFNγ/TNFα
producing cells by day 13 (Figures 2A–E). The medium dose
mice had evidence of only partial exhaustion of their CD8 T cell
response in this same time frame. They had significantly more
of the double positive IFNγ/TNFα producing T cells by all three
epitope-specific CD8 T cell responses on day 7 and day 13 than
did high dose-infected mice, although significantly less than the
low dose group. Expression of the prototypic cell surface marker of
exhaustion, PD-1 (14, 16) on epitope-specific CD8 T cells at day 10
post infection was intermediate in the medium dose as compared
to the high and low dose groups, consistent with partial exhaus-
tion (Figure 2F). There was also a significantly greater portion of
the functional LCMV-GP33 and -NP205-specific CD8 T cells in
the medium dose mice producing three cytokines including IL-2
(Figure 2G). These results would suggest that at the medium dose
www.frontiersin.org December 2013 | Volume 4 | Article 475 | 3
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FIGURE 2 | Partial clonal exhaustion in the LCMV clone 13 medium
dose-infected mice. The functionality of the epitope-specific CD8 T cells in
the three groups of mice was determined by ICS staining for the presence
of IFNγ and/or TNFα-producing cells and calculating the ratio of
IFNγ+TNFα+/IFNγ+ cells at days 7 (A) and 13 (B) post infection in
peripheral blood (A) and spleen (B). The high dose clone 13-infected mice
had significant exhaustion of NP396-, GP33-, and NP205-specific responses
as defined by loss of double producing INFγ/TNFα cells by day 13 (C). The
medium dose mice had evidence of only partial exhaustion of their CD8 T
cell response in this same time frame. They had greater frequency of
IFNγ/TNFα producing cells by all three CD8 epitope-specific responses on
day 7 and day 13 than high dose mice, although significantly less than the
low dose group (NP396: low vs. medium, high vs. low; GP33: low vs.
medium, medium vs. high, high vs. low; NP205: medium vs. high, high vs.
low, **p<0.01; n=5–7 mice/group). (D)The medium dose mice also had
increased total numbers of GP33-specific IFNγ+TNFα+ CD8 T cells in the
spleen at day 13–14 post infection (n=3–6 mice/group pooled from three
experiments). Data analyzed by a one-way ANOVA and Tukey test.
****p<0.0001, **p<0.01, *p<0.05. (E)These medium dose mice also
demonstrated an increased ratio in IFNγ+TNFα+/IFNγ+ producing cells in
the total numbers of GP33-specific cells in the spleen at day 13–14 post
infection than high dose mice. (F) CD8 expression of cell surface marker
PD-1 on epitope-specific cells at day 10 post infection was intermediate in
the medium dose as compared to the high and low dose groups, consistent
with partial exhaustion. This is representative of two similar experiments.
(G)There was also a significantly greater frequency of LCMV-GP33 and
NP205-specific CD8 T cells producing IL-2 and TNFα on day 11 post infection
in the medium dose as compared to the high dose-infected mice
(*p<0.05; n=4 mice/group). These data are representative of two similar
experiments.
of virus the viral load is high enough to result in a partial exhaus-
tion phenotype (6) and these sub-optimally functioning CD8 T
cells are able to mediate the induction of severe immunopathology
leading to death.
INCREASED LUNG AND LIVER PATHOLOGY IN MEDIUM
DOSE-INFECTED MICE
The lung immunopathology in the surviving medium dose mice as
assessed by histology demonstrated severe pulmonary edema and
interstitial infiltrates with consolidation, enhanced bronchus asso-
ciated tissue (BALT), and necrotizing bronchiolitis (Figure 3A).
Using our established method of scoring lung pathology (11–
13) the medium dose mice had significantly more pathology than
either the high and low dose mice or the TCRβ KO and the CD8
T cell-depleted mice, all of which had minimal interstitial infil-
trates, consistent with this being CD8 T cell-mediated pathology
(Figure 4A).
The livers of the medium dose mice also had significantly
increased liver pathology (Figures 3B and 4B) as demonstrated
by increased liver enzyme, alanine aminotransferase (ALT), in
their serum as compared to low dose, TCRβ KO, and CD8 T cell-
depleted mice. Histological sections of the liver showed serious
bridging necrosis in the medium dose mice (Figure 3B), while
the high and low dose mice as well as the TCRβ KO and CD8
depleted medium dose mice had only periportal and sinusoidal
inflammatory infiltrates. We also examined the lymph nodes of
these mice and found that with all three doses of LCMV clone
13 they essentially maintained their normal architecture meaning
that there was recruitment of lymphocytes in T cell zones and
increased numbers of germinal centers with infection but there
was no overall destruction or necrosis of the lymphoid structures
as has been reported for high dose LCMV-WE infection (17, 18)
(data not shown).
DISCUSSION
These results demonstrate that, depending on the initial dose of
non-cytopathic viruses such as LCMV clone 13, a rapidly replicat-
ing virus, disease outcome can differ greatly (Figure 5). The fact
that high dose LCMV clone 13 infection resulted in clonal exhaus-
tion and viral persistence has been previously reported, and is
a well-established model for viral persistence (4–7, 19). As shown
here, the limited pathology occurring after high dose infection sug-
gests that extensive clonal exhaustion may be a beneficial immune
mechanism that prevents death from an overwhelming CD8 T cell
response. The importance of this extensive clonal exhaustion was
demonstrated by using the medium dose of LCMV. At medium
dose LCMV clone 13, the CD8 T cell response was only partially
exhausted, leaving a suboptimal response that was unable to clear
the virus yet persisted at a level of function that caused severe
immune pathology that could kill the host. The medium dose mice
which survived were finally able to exhaust their immune response
and became persistently infected, much like the high dose-infected
mice. Persistent LCMV clone 13 infection is ultimately cleared in
B6 mice by day 60, and epitope-specific CD8 T cells return, except
for the high affinity NP396 T cells, which are eliminated by apop-
tosis (4, 14, 20) in the presence of functional LCMV-specific CD4
T cells (21, 22).
High dose clonal exhaustion has been extensively studied (4–7,
14, 17, 22, 23) and it has been suggested to be a mechanism for
the virus to survive by not killing its host. However, we would
suggest it is also a mechanism of the host to survive high doses of
pathogens whether it is from a very high initial inoculum as may
be received in a direct intravenous infection or from pathogens
that replicate extremely fast (15). For instance, Hepatitis B virus
(HBV) infection can present with a spectrum of disease from an
acute resolving infection to a chronic persistent infection or a very
fulminant hepatitis with high levels of T cells and a sudden and
severe liver destruction and failure (24). In fact, PD-1 expression
on virus-specific CD8 T cells has been correlated with the out-
come of HBV (25). Delayed PD-1 expression on HBV-specific
CD8 T cells was associated with delayed exhaustion of the CD8 T
cell response and subsequent acute liver failure. It is possible that
these three different outcomes can be partially explained by the
fine balance between the HBV load and the efficiency of each indi-
vidual’s CD8 T cell response. Other earlier studies have suggested
that there may be a fine balance between viral dose and the qualita-
tive and quantitative characteristics the CD8 T cell response, which
impacts disease outcome either by infecting genetically modified
mice so that T cell receptor signaling is attenuated (26), or using
mathematical models (27), or transferring in different quantities
of antigen-specific cells prior to challenge with extremely high
doses of virus (28).
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FIGURE 3 | Enhanced immunopathology in the lung and liver during
medium dose LCMV clone 13 infection. (A) Low dose LCMV clone 13
infection i.v. induces mild interstitial infiltrates as demonstrated in
histology (H&E stain) sections of the lung at day 13. Medium dose LCMV
clone 13 infection i.v. induces severe pulmonary edema, interstitial
infiltrates with consolidation, enhanced bronchus associated tissue
(BALT), and necrotizing bronchiolitis. High dose LCMV clone 13 infection
i.v. induced minimal pathology with few interstitial infiltrates. Mice
depleted of CD8 T cells with anti-CD8 mAb or TCRβ KO mice were
protected from severe lung pathology having only minimal interstitial
infiltrates. (B) Histological sections of the liver (H&E stain) showed
serious bridging necrosis in the medium dose LCMV clone 13-infected
mice at day 13, while the high and low dose mice as well as the TCRβ KO
and CD8 depleted medium dose mice had only periportal and sinusoidal
inflammatory infiltrates. Arrows indicate the areas of significant
pathology.
The data presented here are also actually the basis for our obser-
vation that NK cells play a role in controlling T cell exhaustion.
Here, we make the point that T cell exhaustion is a positive event,
which prevents mortality and severe immunopathology. However,
we do not cover all the potential mechanisms which contribute
to the induction of this phenomenon. Our data suggests that the
key inducer of pathology is activated CD8 T cells. However, other
immune cells also contribute by controlling CD8 T cell activa-
tion (like CD4 cells and NK cells). In fact, we recently found that
NK cells act as a rheostat and play a role in regulating CD8 T cell
exhaustion (29). NK cells can kill activated CD4 T cells, resulting in
the loss of CD4-help and exhaustion of CD8 T cells. Another study
found that using different doses of LCMV clone 13 could induce
different levels of weight loss with an intermediate dose causing
the severest weight loss. They also suggested that CD4 cells play a
role in this phenomenon as they showed that ablation of the CD4
T cell response by depletion reverted this phenotype (30).
Our studies could lead to a counter intuitive treatment strat-
egy for other lethal arenaviruses, such as Lassa fever. Perhaps
these patients should be treated short-term with anti-CD3 (31,
32) or anti-CD8 as their immunopathology and death may be T
cell-mediated and preventable. Generalized immunosuppressive
therapy such as corticosteroids may have been tried in the past,
but these treatments would lead to suppression of all aspects of
Frontiers in Immunology | Immunological Memory December 2013 | Volume 4 | Article 475 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cornberg et al. Clonal exhaustion protects against death
FIGURE 4 | Increased pathology in the lung and liver during medium
dose LCMV clone 13 infection. (A)The severity of the lung pathology was
scored using our established histology scale (see Materials and Methods).
The lungs of mice infected with LCMV clone 13 medium dose i.v. had
significantly more severe lung pathology than low dose or high
dose-infected mice at day 13 post infection. This pathology was abrogated
by anti-CD8 mAb treatment or by infecting TCRβ KO mice (**p=0.003,
***p<0.001; n=4–9 mice/group) (B) Severity of liver pathology was
assessed by measuring the levels of the liver enzyme ALT at day 13 post
infection (see Materials and Methods). ALT levels were significantly
increased in medium dose-infected mice as compared to low dose.
Treatment with anti-CD8 at the time of infection with medium dose
prevented this increase in ALT levels. Positive control for this ALT assay is
day 13 mice infected with mouse hepatitis virus (MHV) (N =2) (*p=0.02,
**p=0.008; n= 6–10 mice/group). These data represent two separate
experiments pooled.
FIGURE 5 |The balance between viral load andT cell response
determined the disease outcome of mice inoculated at three different
doses of virus. A low dose of LCMV results in a strong T cell response that
quickly clears virus and causes little immunopathology. At a high dose of
LCMV, the T cell response is clonally exhausted leading to limited
immunopathology even though there is persistent virus. An intermediate
dose of LCMV induces only a partial clonal exhaustion and mice develop
severe immunopathology with up to 75% mortality.
the immune response, leaving the host helpless. Just focusing on
the CD8 T cell responses or even particular CD8 functions may
improve outcome without disabling the complete immune system.
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